Presentation is loading. Please wait.

Presentation is loading. Please wait.

Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,

Published byDelphia Dean Modified over 8 years ago

Similar presentations

Presentation on theme: "Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,"— Presentation transcript:

1 Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC, David Cox, MD, FACC, James Hermiller, MD, FACC, Joseph Massaro, PhD, Joyce Wahr, MD, Sew Wah Tay, PhD, Michael Jonas, MD, Jeffrey J. Popma, MD, FACC, Jim Pavliska, BS, Dennis Wahr, MD, FACC, Campbell Rogers, MD, FACC, for the PROXIMAL Investigators J Am Coll Cardiol 2007;50:1442-49

2 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Overview Background: Embolic complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but not eliminated, by distal protection. Objectives: To improve outcomes further, we investigated an embolic protection device placed proximal to the target lesion that could provide protection before lesion instrumentation, allow use of conventional guidewires, and permit embolic protection in anatomy unfavorable for distal devices.

3 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Background Distal embolic protection using balloon occlusion or filters reduces post- procedural complications during SVG PCI 30 d MACE (%) 0 2 4 6 8 10 12 14 16 18 FIRE Filter Wire 9.9% SAFER unprotected 16.5% 11.6% FIRE Guard Wire 9.6% SAFER Guard Wire PRIDE Tri Active 11.2% PRIDE Filter/ Guard Wire 10.1% Explanations for residual MACE despite distal protection may include embolization during crossing, incomplete capture, and events occurring after device removal

4 Webb et al: JIC, 2005, 18, 1-3 Angiographic Eligibility for Embolic Protection Among SVG PCI Patients Distal (20%) Proximal, non-ostial (18%) Body of Vein Graft (40%)

5 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Study Device Proxis Embolic Protection System (St Jude Medical, Maple Grove, MN) Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply.

6 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Methods 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, using a non- inferiority design to compare two treatment strategies: Control (distal protection whenever possible) or Test (proximal protection when possible, distal when not). The study was designed to test whether a treatment strategy in which proximal protection was used whenever possible would be non-inferior to a strategy of distal protection only. Rejection of the null hypothesis would indicate that the proximal protection strategy would have a primary endpoint rate (30 day MACE) not exceeding that of the distal protection strategy plus a pre-specified non- inferiority margin.

7 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 30 Day MACE: Death, MI (CPK-MB ≥3x ULN), urgent CABG, or Target Vessel Revascularization Power analysis: Assumed event rate for control arm = 12.7% Delta = 7% (55% relative delta) One sided α=0.05 for non-inferiority 560 randomized pts provides 80% power for non- inferiority  600 pts planned PROXIMAL: Primary Endpoint

8 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Major Criteria Inclusion: Normal CK/CKMB Lesion(s) in SVG is ≥50% and <100%. Up to 2 SVGs. No limit on number of lesions Concomitant 1-2 native vessel PCI allowed ≥TIMI I Flow Device landing zone RVD ≥3.0 and  5.0 mm Exclusion: MI with 24 hours Cardiac Surgery within 60 days Lesion(s) within 5 mm of proximal anastomotic site LVEF < 20% More than 2 native lesions to be treated More that 2 SVGs to be treated

9 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Study Algorithm FilterWire/ GuardWire Control FilterWire/ GuardWire Proxis Randomization No protection Proxis FilterWire/ GuardWire Proxis Proxis™ system Test arm: Use Proxis™ system whenever possible, and FW or GW when Proxis not possible (proximal lesions) Control arm: Use FW/GW whenever possible, and no protection when FW/GW not possible (distal lesions) SVG PCI 594 pts Stratified by GP IIb/IIIa use

10 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. The PROXIMAL Trial

11 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Baseline Clinical Features ControlTestP value N patients300294- Age (mean yrs)70+ 969 + 10NS Male gender84%87%NS Diabetes mellitus44%43%NS Hypertension89%86%NS Hyperlipidemia91% NS Smoker22%20%NS Prior MI60%59%NS Class III/IV angina75%78%NS LVEF (%)48 + 1248 + 14NS GP IIb/IIIa blocker use (%) 42.341.5NS

12 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Baseline Angiographic Features ControlTestP value N patients300294- SVG distribution0.029 - Left Anterior Descending16.6%23.3%NS - Left Circumflex45.1%36.1%NS Right Coronary Artery38.3%40.6%NS Reference Vessel Diameter (mm)3.22 ± 0.603.28 ± 0.60NS Minimal Lumen Diameter (mm)1.05±0.501.04±0.49NS Diameter stenosis (%)67.32±13.7168.35±13.35NS SVG degeneration score39.32±21.2839.10±21.84NS Plaque Volume105.4±92.5114.1±98.1NS

13 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Δ = -0.8 [-4.8, +3.2] P = 0.0061 for NI Primary Endpoint (30 Day MACE): Intention to Treat

14 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Actual Devices Used Test arm Control arm * *81% FilterWire, 19% GuardWire

15 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. 30-Day MACE Rates

16 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 30 Day MACE: “By Device” Analysis Δ = -4.6 [upper bound 95% CI -0.05] P = 0.0001 for NI *No protection: Primarily distal lesions randomized to Control Arm *

17 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 FilterWire/ GuardWire Control FilterWire/ GuardWire Proxis Randomization No protection Proxis FilterWire/ GuardWire Proxis Secondary Analysis: Outcomes in Patients With Lesions Suitable for Either Proximal or Distal Protection

18 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 30 Day MACE: Lesions Amenable to Either Proximal or Distal Protection Δ = -3.1 [-8.2, +2.0] P = 0.089 for superiority, P = 0.0001 for NI

19 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Periprocedural Myonecrosis by Intention-to-Treat Analysis Population

20 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Mauri, L. et al. J Am Coll Cardiol 2007;50:1442-1449 Periprocedural Myonecrosis by Device Analysis Population

21 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Mauri, L. et al. J Am Coll Cardiol 2007;50:1442-1449 Periprocedural Myonecrosis by Patients Eligible for Treatment With Either Device

22 Mauri L. et. al. J Am Coll Cardiol 2007;50:1442-49 PROXIMAL: Conclusion A treatment strategy that included proximal embolic protection whenever possible during treatment of SVG lesions produced outcomes similar to those seen with a strategy using only distal embolic protection. These results support use of proximal protection in eligible lesions.

Download ppt "Proximal Protection during Saphenous Vein Graft Intervention using the Proxis™ Embolic Protection System The PROXIMAL Trial Laura Mauri, MD, MSc, FACC,"

Similar presentations

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
THE USE OF HISTORICAL CONTROLS IN DEVICE STUDIES Vic Hasselblad Duke Clinical Research Institute.

THE USE OF HISTORICAL CONTROLS IN DEVICE STUDIES Vic Hasselblad Duke Clinical Research Institute.
Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.

Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.
Caution: Investigational Device. Limited by Federal (USA) Law to investigational use. AMEthyst The AMEthyst Trial A prospective randomized controlled study.

Caution: Investigational Device. Limited by Federal (USA) Law to investigational use. AMEthyst The AMEthyst Trial A prospective randomized controlled study.
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY

FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation

FFR vs Angiography for Multivessel Evaluation
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.

CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ 2008-1 Thrombus Aspiration during Percutaneous coronary intervention in Acute.

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,

The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results.

The Radial Artery Patency Study Investigators Radial Artery and Saphenous Vein Patency more than 5-years Following Coronary Artery Bypass Surgery: Results.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.

Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
SPIDER Saphenous Vein Graft Protection In a Distal Embolic Protection Randomized Trial Simon R. Dixon MBChB, William W. O’Neill MD William Beaumont Hospital,

SPIDER Saphenous Vein Graft Protection In a Distal Embolic Protection Randomized Trial Simon R. Dixon MBChB, William W. O’Neill MD William Beaumont Hospital,
Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.

Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.

Similar presentations

Ads by Google